Clinical Trials in the EU / 2026-527244-40-00
Authorised, not yet recruiting
Phase I
Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Risk of Thromboembolic Events
2026-527244-40-00 · tracked via the Priya Life Science EU tracker
Condition studied
Thromboembolic Events
Eligibility
Primary endpoint
Plasma milvexian Cmax, tmax, AUC∞, AUClast, and t1/2
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-527244-40-00 on CTIS ↗ ← All trials in the EU